KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Before 2028 92%Koploper van 5 uitkomsten
Marktkwaliteit
46 / 100
Lage kwaliteit24u volume
—
Liquiditeit
€ 7,2K
Gemiddelde liquiditeitSpread
5.0 pt
Gematigde spreadMarktdata
Bijgewerkt 10 minuten geleden
16 mei 26, 02:30 UTC1 jan 27, 04:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
When will Compass Pathways submit a NDA for COMP360 psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiRegels
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Open markten
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No+0.4pt97%
- Yes-0.4pt3%
- Totaal volume
- € 15,7 mln.
- 24u volume
- € 52,2K
KALSHIMeasles cases in 2026?
- Above 4000+2.0pt99%
- Above 300099%
- Above 600061%
+2 extra uitkomsten
- Totaal volume
- € 870,4K
- 24u volume
- € 2,1K
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Totaal volume
- € 922,5K
- 24u volume
- € 1,8K
KALSHICyclosporiasis cases reported in the US in 2026?
- Above 18k99%
- Above 6k99%
- Above 10k99%
+12 extra uitkomsten
- Totaal volume
- € 32,4K
- 24u volume
- € 1,3K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes+0.4pt3%
- Totaal volume
- € 1,6 mln.
- 24u volume
- € 933,9
KALSHIHealthcare AI adoption in September
- Above 43%87%
- Above 43.75%59%
- Above 45%14%
+4 extra uitkomsten
- Totaal volume
- € 810,1
- 24u volume
- € 767
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- Measles cases in U.S. by September 30?
- What will the average number of measles cases be during Trump's term?
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Will the FDA approve any psychedelic substance for medical use this year?
- Pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- Ebola: new country confirmed before October 1?
Veelgestelde vragen
- Wat zijn de huidige kansen voor When will the FDA approve Compass Pathways' COMP360 Psilocybin??
- Kalshi prijst Before 2028 op 92% per 11 september 2026.
- Wanneer wordt When will the FDA approve Compass Pathways' COMP360 Psilocybin? afgewikkeld?
- When will the FDA approve Compass Pathways' COMP360 Psilocybin? wordt naar verwachting op 1 januari 2027 afgewikkeld.
- Hoe wordt When will the FDA approve Compass Pathways' COMP360 Psilocybin? afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.